Life Technologies Corporation

Life Technologies Corporation, a wholly owned subsidiary of Thermo Fisher Scientific Inc. headquartered in Grand Island, New York, supplies specialized biomedical research instruments, genetic analysis equipment, immunoassay systems, molecular diagnostic reagents, and laboratory consumables to federal health, research, and defense agencies as a prime contractor under full-and-open competition with no small-business certifications or set-asides. The company operates exclusively in unrestricted federal markets and competes on the basis of proprietary technology and established customer relationships rather than small-business designations.

Life Technologies' federal footprint spans 103 customer agencies across roughly 3,000 awards with combined potential value of $280.5 million, though dollars obligated stand at $76 million (27% of ceiling). Recent activity declined from 64 awards in 2022 to 16 in 2026 year-to-date, reflecting a concentrated pipeline of high-value orders rather than volume growth. The company's capability portfolio centers on genetic analysis platforms (Applied Biosystems and QuantStudio real-time PCR systems, Ion Torrent next-generation sequencers, 3500XL genetic analyzers), multiplexed immunoassay systems (Luminex xMAP INTELLIFLEX platforms, ProcartaPlex kits), flow cytometry and imaging equipment (Attune CytPix, EVOS microscopy systems), and proprietary molecular diagnostic reagents (TaqMan master mixes and probes, BigDye Terminator sequencing kits, custom PCR assays, magnetic bead purification systems). Representative prime work includes a $208.6 million FBI Headquarters Division delivery order for biomedical research instruments and reagents (September 2026, Grand Island, NY, firm fixed price through December 2026); a $200 million single-award indefinite-delivery contract with the Department of Health and Human Services for laboratory reagents and consumables (September 2026 award, ceiling through February 2032); a $4.5 million FBI delivery order for instruments and reagents (September 2026); a $15.7 million VA Integrated Service Network 9 assurance agreement for Attune NXT 4 laser maintenance (September 2026 through September 2027); and a $128.8 million Bureau of Medicine and Surgery purchase order for molecular diagnostic reagents supporting NAMRU-South operations in Lima, Peru (August 2025).

Customer concentration diverges between volume and dollars. By award count, the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh leads with 159 awards ($8.8 million combined value), followed by CDC Office of Acquisition Services (120 awards, $3.2 million), the National Cancer Institute (95 awards, $2.4 million), and the Navy Bureau of Medicine and Surgery (95 awards, $8 million). By potential value, the Federal Bureau of Investigation dominates with 29 awards carrying $208.6 million (about 74% of combined potential value across the top five customers), followed by the HHS Office of the Assistant Secretary for Administration (29 awards, $15.4 million), CDC Pittsburgh (159 awards, $8.8 million), Navy Bureau of Medicine and Surgery (95 awards, $8 million), and CDC Office of Acquisition Services (120 awards, $3.2 million). This concentration in FBI awards reflects a single large vehicle rather than broad civilian health-agency penetration.

Life Technologies places task orders under five named parent vehicles: a Blanket Purchase Agreement (EPBPA12W0013) with 17 task orders valued at $281 thousand; an Indefinite Delivery Contract (75N91018D00037) with 7 task orders, $247 thousand; Federal Supply Schedule V797P5253N with 7 task orders (value not specified); an Indefinite Delivery Contract (36C25620D0100) with 5 task orders, $69 thousand; and an Indefinite Delivery Contract (DJF171200V0005697) with 4 task orders, $97 thousand. The company also holds a single-award indefinite-delivery contract with HHS (September 2026 award, $200 million ceiling through February 2032) and a single-award BPA with VA Veterans Integrated Service Network 15 for pathology and laboratory sequencing reagents (July 2023 through June 2024, $1.45 million).

Recompete risk is moderate: 12 awards with combined potential value of $5.2 million reach ultimate completion inside the next twenty-four months. Recent subcontract work includes annual service agreements for ABI 7500 Fast qPCR machines and Life Technologies instrument maintenance performed under the Department of Homeland Security contract (HSHQDC-15-C-00064) with Battelle National Biodefense Institute to operate the National Biodefense Analysis and Countermeasures Center at Fort Detrick, Maryland (awards March 2026, March 2026, May 2025, March 2025, February 2025, November 2024, April 2024, February 2024). Grant sub-award work includes consumable supplies and maintenance provided to the Attorney General of Ohio (July 2023).

Life Technologies competes across three dominant NAICS categories: Analytical Laboratory Instrument Manufacturing (474 awards), Biological Product Manufacturing except Diagnostic (326 awards), and In-Vitro Diagnostic Substance Manufacturing (270 awards). PSC distribution is concentrated in Laboratory Equipment and Supplies (1,759 awards), Chemicals (405 awards), Medical and Surgical Instruments, Equipment, and Supplies (181 awards), Drugs and Biologicals (177 awards), and In Vitro Diagnostic Substances, Reagents, Test Kits and Sets (173 awards). The company's proprietary technology position—particularly in TaqMan reagents, Applied Biosystems platforms, and Luminex systems—anchors sole-source and competitive awards across health agencies, with no material subcontract footprint or small-business teaming relationships in the source data.